LAVAL, Quebec, June 30, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti) (TSX-V:APO), a subsidiary of Neptune Technologies & Bioressources Inc. (Neptune), has received a positive response from Health Canada regarding its previously announced Clinical Trial Application (CTA), thereby allowing the initiation of a phase II clinical trial with CaPre®.
